Microglial phagocytosis is the process by which microglia—the resident immune cells of the central nervous system—identify, engulf, and eliminate cellular debris, protein aggregates, and dead cells. This function is essential for maintaining brain homeostasis and is particularly critical in neurodegenerative diseases where pathological protein accumulation occurs.
In healthy brains, microglia continuously perform surveillance and phagocytose debris as part of normal immune surveillance. However, in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and ALS, microglial phagocytosis becomes profoundly dysregulated, contributing to disease progression through both protective and pathological mechanisms[1].
The triggering receptor expressed on myeloid cells 2 (TREM2) is the most significant microglial receptor for phagocytosis in neurodegeneration. TREM2 is expressed exclusively on microglia in the brain and binds to anionic surfaces including:
Upon ligand binding, TREM2 signals through the adaptor protein DAP12 (TYROBP), which contains an immunoreceptor tyrosine-based activation motif (ITAM). This triggers downstream signaling cascades:
| Receptor | Ligand | Function |
|---|---|---|
| CD36 | Aβ fibrils, apoptotic cells | Collaborative phagocytosis with TREM2 |
| SR-AI/II | Modified proteins, lipids | Scavenger receptor-mediated uptake |
| CR3 (CD11b/CD18) | iC3b opsonized particles | Complement-mediated phagocytosis |
| Fcγ receptors | Antibody-opsonized targets | Immunoglobulin-mediated clearance |
| MerTK | Apoptotic cells | Tyrosine kinase receptor for efferocytosis |
The TREM2 R47H variant (and other rare coding variants) increases AD risk by approximately 3-4-fold, equivalent to one APOE4 allele. These variants cause a loss of function in phagocytosis, leading to:
In AD, microglial phagocytosis has a complex, context-dependent role:
Protective functions:
Pathological consequences:
In PD, microglial phagocytosis targets:
TREM2 deficiency in PD models leads to:
Microglial phagocytosis in ALS:
| Approach | Mechanism | Development Stage |
|---|---|---|
| Anti-Aβ immunotherapies | Reduce substrate load for microglia | Approved (lecanemab, donanemab) |
| CSF1R antagonists | Reduce microglial proliferation | Clinical trials |
| Tyrostatins | Inhibit TREM2 cleavage | Preclinical |
| Pro-resolving mediators | Shift from inflammatory to resolving phenotype | Preclinical |
The dysfunction of microglial phagocytosis represents a critical therapeutic target in neurodegenerative diseases. Understanding how to modulate microglial phagocytic capacity has led to several clinical strategies.
The central role of TREM2 in microglial phagocytosis has made it a prime therapeutic target:
Beyond direct TREM2 targeting, several approaches aim to shift microglial phenotype toward a phagocytosis-competent state:
Quantifying microglial phagocytic capacity in vivo remains challenging, but several biomarker approaches are emerging:
Several clinical trials are targeting microglial function in neurodegenerative diseases:
Dysfunctional microglial phagocytosis contributes to disease progression through multiple mechanisms:
Early intervention targeting microglial phagocytosis may:
Key challenges remain in translating microglial phagocytosis research to clinical practice:
Recent advances in microglial phagocytosis research have elucidated the role of microglia in clearing protein aggregates and cellular debris in neurodegenerative diseases.
The triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein of the immunoglobulin superfamily. Its structure includes:
The TREM2 R47H variant, which increases AD risk 3-4 fold, shows reduced ligand binding affinity. This highlights the importance of understanding TREM2-ligand interactions for therapeutic development.
Upon TREM2 ligand binding, DAP12's ITAM motif is phosphorylated by Src family kinases, leading to SYK recruitment and activation. This triggers multiple downstream pathways:
PI3K/Akt pathway: Critical for cytoskeletal reorganization and phagocytic cup formation. Akt phosphorylation promotes actin polymerization and phagosome closure.
MAPK/ERK pathway: Enhances cellular proliferation and survival. ERK activation also contributes to inflammatory gene expression.
NF-κB pathway: Modulates expression of inflammatory cytokines and complement proteins. NF-κB activation can be both protective and pathological depending on context.
Multiple receptors cooperate in microglial phagocytosis:
TREM2-CD36 collaboration: CD36 works with TREM2 to enhance phagocytosis of amyloid-β fibrils. CD36 also mediates oxidized LDL uptake and contributes to foam cell formation.
TREM2-FcγR cooperation: Fcγ receptors recognize antibody-opsonized targets. TREM2 and FcγR signaling converge on SYK, creating synergistic phagocytic responses.
Complement receptor协同: CR3 (Mac-1) and TREM2 both contribute to phagocytosis of complement-opsonized particles. This redundancy ensures robust clearance but can lead to excessive pruning.
In AD, microglial phagocytosis operates in a highly challenging environment:
Plaque-associated microglia: Microglia surrounding plaques show a unique transcriptional state (DAM or disease-associated microglia). These cells upregulate phagocytic genes but often fail to clear plaque effectively.
Metabolic dysfunction: Microglial metabolism becomes impaired in AD, affecting ATP production for phagosome maturation. The glycolytic shift seen in activated microglia may not adequately support phagocytic demands.
TREM2 polymorphism impact: TREM2 R47H carriers show increased plaque burden, reduced microglial clustering around plaques, and faster disease progression. This demonstrates the critical role of microglial phagocytosis in controlling Aβ accumulation.
Microglial phagocytosis of α-synuclein presents unique challenges:
Aggregated α-synuclein: Unlike Aβ fibrils, α-synuclein aggregates can be taken up by microglia but often resist lysosomal degradation. This can lead to microglial death and inflammatory spread.
Neuromelanin: The dark pigment in dopaminergic neurons is released from dying cells and phagocytosed by microglia. Neuromelanin-containing microglia are abundant in PD substantia nigra.
LRRK2 G2019S: This common PD-causing mutation enhances microglial proliferation and may alter phagocytic function. LRRK2 is expressed in microglia and localizes to phagosomes.
Motor neuron disease involves complex microglial responses:
SOD1 aggregates: Mutant SOD1 is released from motor neurons and phagocytosed by microglia. However, microglia Show impaired clearance of SOD1 aggregates.
TDP-43 pathology: TDP-43 aggregates in ALS are also subject to microglial phagocytosis. The efficiency of this clearance may influence disease progression.
Proliferative response: Microglia proliferate extensively in ALS spinal cord, forming dense clusters around motor neurons. This-reactive state may contribute to neurotoxicity.
Several strategies aim to enhance TREM2 function:
Agonistic antibodies: Monoclonal antibodies binding the TREM2 extracellular domain can enhance receptor signaling. These are being developed for AD treatment.
Small molecule agonists: Oral, brain-penetrant small molecules that enhance TREM2 signaling are in preclinical development.
Gene therapy: AAV-mediated TREM2 delivery to the brain could provide long-term enhancement of microglial phagocytosis.
Colony-stimulating factor 1 receptor (CSF1R) regulates microglial survival and proliferation:
CSF1R antagonists: PLX3397 (pexidartinib) and PLX5622 deplete microglia and are used experimentally. While reducing pathological microglia, this approach may also remove protective populations.
CSF1R agonists: Conversely,CSF1R activation could enhance microglial function. However, this approach risks promoting pathological microglial expansion.
Microglial phagocytosis requires substantial metabolic support:
Glycolytic enhancement: Promoting glycolysis may improve phagocytic capacity. PFKFB3 activators are being explored for this purpose.
Mitochondrial function: Supporting mitochondrial metabolism could enhance phagosome maturation. CoQ10 and other mitochondrial supplements have been tested in neurodegenerative diseases.
| Biomarker | Source | Interpretation |
|---|---|---|
| sTREM2 | CSF | Microglial activation; rises early in AD |
| YKL-40 | CSF | Chitinase-3-like protein; astrocyte/microglia activation |
| MCP-1/CCL2 | CSF | Monocyte chemoattractant; inflammation marker |
| IL-6, IL-1β | CSF | Pro-inflammatory cytokines |
TSPO PET: Formerly used to image microglial activation, but lacks specificity for beneficial vs. harmful activation.
Novel ligands: Newer PET tracers aim to distinguish microglial phenotypes, enabling more targeted therapeutics.
Single-cell RNA sequencing has revealed microglial heterogeneity:
Understanding these populations informs therapeutic targeting.
iPSC-derived microglia: Patient-derived microglia allow study of genetic variants.
Organoid systems: Brain organoids with microglia-like cells model development and disease.
Microfluidic devices: These enable study of microglial migration and phagocytosis in controlled environments.
Small molecule TREM2 agonists offer advantages over antibodies:
Current candidates in development show:
While CSF1R antagonists deplete microglia, benefits must be weighed:
Potential benefits:
Risks:
Viral vector delivery of functional TREM2:
AAV serotypes: AAV-PHP.B and AAV9 show good CNS transduction.
Promoters: Synapsin or GFAP promoters restrict expression to neural cells.
Therapeutic outcomes: Preclinical studies show improved plaque clearance.
Microglial phagocytosis declines with age:
Receptor expression: TREM2 and other phagocytic receptors show altered expression.
Metabolic capacity: Reduced ATP production impairs phagosome maturation.
Inflammatory phenotype: Aged microglia adopt a pro-inflammatory, phagocytosis-suppressive state.
Caloric restriction: Improves microglial phagocytic function in aged mice.
Exercise: Enhances microglial motility and phagocytosis.
Pharmacological: Certain drugs (e.g., nanomedicines) can enhance aged microglial function.
Estrogen: Modulates microglial phagocytosis; potentially protective in females.
Progesterone: Anti-inflammatory effects may alter phagocytic responses.
Testosterone: May suppress microglial activation in males.
Sex differences have implications for:
sTREM2: Soluble TREM2 in CSF correlates with microglial activation.
YKL-40: Chitinase-3-like protein indicates microglial/astrocytic activation.
CSF cytokines: IL-1β, TNF-α reflect inflammatory state.
Microglial phagocytosis in AD shows both protective and harmful effects:
Protective functions:
Harmful functions:
The balance shifts with disease progression - early phagocytosis may be protective while later stages show dysfunction.
TREM2 agonists: Currently in development to boost microglial phagocytosis:
CSF1R modulation: Balancing microglial survival and function:
CD33 inhibition: Genetic association with AD risk:
Complement inhibition: Preventing synapse tagging:
TREM2 modulation: When phagocytosis becomes excessive:
Cytokine modulation: Reducing inflammatory triggers:
Microglial phagocytosis occurs within broader neuroinflammation:
Triggering:
Mediators:
Resolution: